| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | RAF265 | CTRPv2 | pan-cancer | AAC | -0.0044 | 0.9 |
| mRNA | WZ3105 | GDSC1000 | pan-cancer | AAC | -0.0032 | 0.9 |
| mRNA | GW843682X | CTRPv2 | pan-cancer | AAC | 0.0037 | 0.9 |
| mRNA | myriocin | CTRPv2 | pan-cancer | AAC | -0.0084 | 0.9 |
| mRNA | BRD-K30748066 | CTRPv2 | pan-cancer | AAC | -0.013 | 0.9 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | 0.003 | 0.9 |
| mRNA | AZ628 | GDSC1000 | pan-cancer | AAC | 0.0051 | 0.9 |
| mRNA | KH-CB19 | CTRPv2 | pan-cancer | AAC | -0.0047 | 0.9 |
| mRNA | selumetinib:decitabine (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0034 | 0.9 |
| mRNA | etomoxir | CTRPv2 | pan-cancer | AAC | 0.0038 | 0.9 |